2-((naphthalen-2-yl)methyl)phenol | 68299-60-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-((naphthalen-2-yl)methyl)phenol
• 英文别名: 2-(2-naphthylmethyl)phenol；2-Hydroxy-1-(naphthyl-(2)-methyl)-benzol；2-[2]Naphthylmethyl-phenol；2-<2-Hydroxy-benzyl>-naphthalin；o-(β-Naphthylmethyl)phenol；2-(Naphthalen-2-ylmethyl)phenol
• CAS: 68299-60-5
• 化学式: C₁₇H₁₄O
• 分子量: 234.298
• InChiKey: QQMADGUPSOVUKB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-((naphthalen-2-yl)methyl)phenol 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 二氯双(三邻甲苯膦)合钯(II) 、 四丁基溴化铵 、 potassium acetate 、 sodium carbonate 、 potassium carbonate 、 三(邻甲基苯基)磷 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 氯仿 、 水 、 丙酮 为溶剂， 反应 3.5h， 生成 ethyl 2-(1,1'-biphenyl-3,3'-di(naphthalen-2-yl)methyl-4'-[2-(dimethylamino)ethoxy]-4-oxy) acetate
  参考文献：
  名称：

  4,4′-Unsymmetrically substituted 3,3′-biphenyl alpha helical proteomimetics as potential coactivator binding inhibitors

  摘要：

  A series of unsymmetrically substituted biphenyl compounds was designed as alpha helical proteomimetics with the aim of inhibiting the binding of coactivator proteins to the nuclear hormone receptor coactivator binding domain. These compounds were synthesized in good overall yields in seven steps starting from 2-bromoanisole. The final products were evaluated using cotransfection reporter gene assays and mammalian two-hybrid competitive inhibition assays to demonstrate their effectiveness as competitive binding inhibitors. The results from this study indicate that these proteomimetics possess the ability to inhibit coactivator-receptor interactions, but via a mixed mode of inhibition. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.10.051
• 作为产物：
  描述：

  (2-hydroxyphenyl)(naphthalen-2-yl)methanone 生成 2-((naphthalen-2-yl)methyl)phenol
  参考文献：
  名称：

  Huisgen,R.; Zahler,W.D., Chemische Berichte, 1963, vol. 96, p. 747 - 764

  摘要：

  DOI：

文献信息

• Synthesis of polycyclic xanthenes and furans via palladium-catalyzed cyclization of polycyclic aryltriflate esters
  作者：Ji-Quan Wang、Ronald G Harvey

  DOI：10.1016/s0040-4020(02)00534-3

  日期：2002.7

  Palladium-catalyzed cyclization of polycyclic aromatic o-(arylmethyl)phenol triflate esters takes place with unexpected sulfur–oxygen bond cleavage to furnish polycyclic xanthenes. These are the first examples of Pd-catalyzed cross-coupling of aryl triflate esters with arenes to form diaryl ethers. In contrast, analogous palladium-catalyzed cyclization of polycyclic o-(aryloxy)phenol triflate esters

  钯催化的多环芳族邻-（芳基甲基）苯酚三氟甲酸酯酯的环化反应发生意外的硫-氧键裂解，从而提供了多环黄嘌呤。这些是芳基三氟甲磺酸酯与芳烃经钯催化交联形成二芳基醚的第一个例子。相反，类似的钯催化多环邻-（芳氧基）苯酚三氟甲酸酯酯的环化反应是通过一种机理进行的，该机理涉及常规的碳-氧键裂解，以提供二芳基呋喃。
• Disubstituted lavendustin A analogs and pharmaceutical compositions comprising the analogs
  申请人：THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

  公开号：EP1367046A9

  公开（公告）日：2004-05-12

  Disubstituted lavendustin A analogs that are PTK inhibitors having antiproliferative activity are described. Preferred compounds of the present invention, without limitation, satisfy either Formula 1 or Formula 2. Currently preferred compounds ,based on in vivo biological activity, are 4'-adamantylbenzoate-1'-N-1,4-dihydroxybenzylamine and 4'-adamantylmethylbenzoate-1'-N-1,4-dihydroxybenzylamine. The present invention also provides pharmaceutical compositions comprising effective amounts of disubstituted lavendustin A analogs. Such compositions also may comprise other active ingredients, other materials conventionally used in the formulation of pharmaceutical composition, and mixtures thereof. The compounds and compositions of the present invention can be used for treating subjects to, for example, inhibit the proliferation of living cells in the treatment of proliferative diseases.

  描述了具有抗增殖活性的PTK抑制剂的二取代拉文杜斯汀A类似物。本发明的优选化合物，不受限于，满足Formula 1或Formula 2中的任一种。根据体内生物活性，目前优选的化合物是4'-金刚烷基苯甲酸酯-1'-N-1,4-二羟基苯乙胺和4'-金刚烷基甲基苯甲酸酯-1'-N-1,4-二羟基苯乙胺。本发明还提供了含有二取代拉文杜斯汀A类似物有效量的药物组合物。这种组合物还可以包括其他活性成分、传统用于制备药物组合物的其他材料以及它们的混合物。本发明的化合物和组合物可用于治疗受试者，例如，在治疗增殖性疾病中抑制活细胞的增殖。
• Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs
  申请人：THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

  公开号：EP1367046A1

  公开（公告）日：2003-12-03

  Disubstituted lavendustin A analogs that are PTK inhibitors having antiproliferative activity are described. Preferred compounds of the present invention, without limitation, satisfy either Formula 1 or Formula 2. Currently preferred compounds ,based on in vivo biological activity, are 4'-adamantylbenzoate-1'-N-1,4-dihydroxybenzylamine and 4'-adamantylmethylbenzoate-1'-N-1,4-dihydroxybenzylamine. The present invention also provides pharmaceutical compositions comprising effective amounts of disubstituted lavendustin A analogs. Such compositions also may comprise other active ingredients, other materials conventionally used in the formulation of pharmaceutical composition, and mixtures thereof. The compounds and compositions of the present invention can be used for treating subjects to, for example, inhibit the proliferation of living cells in the treatment of proliferative diseases.

  本发明描述了具有抗增殖活性的 PTK 抑制剂--二取代的拉芬多汀 A 类似物。本发明的优选化合物不限于满足式 1 或式 2。根据体内生物活性，目前优选的化合物是 4'-金刚烷基苯甲酸-1'-N-1,4-二羟基苄胺和 4'-金刚烷基甲基苯甲酸-1'-N-1,4-二羟基苄胺。本发明还提供了包含有效量的二取代拉芬多汀 A 类似物的药物组合物。此类组合物还可包含其他活性成分、用于配制药物组合物的其他常规材料及其混合物。本发明的化合物和组合物可用于治疗受试者，例如在治疗增殖性疾病时抑制活细胞的增殖。
• Recognition of Emotion in Facial Expressions and Vocal Tones in Children With Psychopathic Tendencies
  作者：D. Stevens、T. Charman、R. J. R. Blair

  DOI：10.1080/00221320109597961

  日期：2001.6

  The authors investigated the ability of children with emotional and behavioral difficulties, divided according to their Psychopathy Screening Device scores (P. J. Frick & R. D. Hare, in press), to recognize emotional facial expressions and vocal tones. The Psychopathy Screening Device indexes a behavioral syndrome with two dimensions: affective disturbance and impulsive and conduct problems. Nine children with psychopathic tendencies and 9 comparison children were presented with 2 facial expression and 2 vocal tone subtests from the Diagnostic Analysis of Nonverbal Accuracy (S. Nowicki & M. P. Duke, 1994). These subtests measure the ability to name sad, fearful, happy, and angry facial expressions and vocal affects. The children with psychopathic tendencies showed selective impairments in the recognition of both sad and fearful facial expressions and sad vocal tone. In contrast, the two groups did not differ in their recognition of happy or angry facial expressions or fearful, happy, and angry vocal tones. The results are interpreted with reference to the suggestion that the development of psychopathic tendencies may reflect early amygdala dysfunction (R. J. R. Blair, J. S. Morris, C. D. Frith, D. I. Perrett, & R. Dolan, 1999).
• DNA damaging agents in combination with tyrosine kinase inhibitors
  申请人：ARCH Development Corporation

  公开号：US20040077087A1

  公开（公告）日：2004-04-22

  The present invention relates to the signalling pathways connecting DNA damage, such as that induced by ionizing radiation or alkylating agents, and phosphorylation by tyrosine kinases.